SAB Biotherapeutics (NASDAQ:SABS) Receives “Buy” Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report published on Monday, Benzinga reports. They currently have a $25.00 price target on the stock.

SABS has been the topic of a number of other research reports. Oppenheimer started coverage on SAB Biotherapeutics in a research report on Wednesday, August 28th. They set an outperform rating and a $12.00 price objective on the stock. Brookline Capital Management began coverage on SAB Biotherapeutics in a report on Friday, June 7th. They set a buy rating and a $8.00 price target on the stock. Finally, HC Wainwright reaffirmed a buy rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $12.75.

SAB Biotherapeutics Stock Up 1.8 %

NASDAQ:SABS opened at $2.80 on Monday. SAB Biotherapeutics has a twelve month low of $2.16 and a twelve month high of $10.50. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.07. The stock’s 50-day simple moving average is $2.76 and its 200 day simple moving average is $3.54.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.34. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. The company had revenue of $0.26 million for the quarter. Equities analysts predict that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

A number of large investors have recently bought and sold shares of SABS. RTW Investments LP bought a new stake in SAB Biotherapeutics in the fourth quarter worth approximately $6,310,000. BVF Inc. IL bought a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $6,310,000. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics during the 4th quarter worth approximately $1,259,000. Finally, First PREMIER Bank bought a new stake in shares of SAB Biotherapeutics in the 2nd quarter valued at $60,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.